Opiant Pharmaceuticals (NASDAQ: OPNT) and Sinovac Biotech (NASDAQ:SVA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Insider & Institutional Ownership

30.7% of Sinovac Biotech shares are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Opiant Pharmaceuticals and Sinovac Biotech, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Sinovac Biotech 0 0 0 0 N/A

Valuation and Earnings

This table compares Opiant Pharmaceuticals and Sinovac Biotech’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $14.97 million 4.56 $5.99 million $2.89 11.66
Sinovac Biotech $64.02 million 6.28 -$837,000.00 ($0.08) -88.21

Opiant Pharmaceuticals has higher revenue, but lower earnings than Sinovac Biotech. Sinovac Biotech is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Opiant Pharmaceuticals and Sinovac Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals 35.68% 386.36% 79.71%
Sinovac Biotech N/A N/A N/A

Summary

Opiant Pharmaceuticals beats Sinovac Biotech on 6 of the 9 factors compared between the two stocks.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.